Membranous PODXL expression by polyclonal antibody HPA 2110 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.

Immunophenotypes of pancreatic ductal adenocarcinoma:Meta-analysis of transcriptional subtypes

de Santiago, Ines
Yau, Christopher
Heij, Lara
Middleton, Mark R.
Markowetz, Florian
Grabsch, Heike
Dustin, Michael L.
Sivakumar, Shivan

August 2019

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of...

Measurement of serum PODXL concentration for detection of pancreatic cancer

Taniuchi K
Tsuboi M
Sakaguchi M
Saibara T

March 2018

Keisuke Taniuchi,1,2 Makiko Tsuboi,2 Masahiko Sakaguchi,3,4 Toshiji Saibara1,2 1Department of Endos...

Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only

Ottenhof, Niki A.
Morsink, Folkert H. M.
ten Kate, Fiebo
van Noorden, Cornelis J. F.
Offerhaus, G. Johan A.

January 2012

Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rat...

Immunohistochemical staining pattern of PODXL by polyclonal antibody HPA 2110 in pancreatic ductal adenocarcinoma.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative...

Concomitant positivity by two PODXL antibodies.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Cancer-specific survival analysis according to the Kaplan-Meier method for combined expression of...

Immunohistochemical staining pattern of PODXL by monoclonal antibody HES9 in pancreatic ductal adenocarcinoma.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative...

RESEARCH ARTICLE Podocalyxin Is a Marker of Poor Prognosis in

Pancreatic Ductal Adenocarcinoma
Kapo Saukkonen
Jaana Hagström
Harri Mustonen
Anne Juuti
Stig Nordling
Christian Fermér
Olle Nilsson
Caj Haglund

August 2016

Aim of the Study Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates...

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma

Saukkonen Kapo
Hagström Jaana
Mustonen Harri
Juuti Anne
Nordling Stig
Fermér Christian
Nilsson Olle
Seppänen Hanna
Haglund Caj

June 2015

Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers ...

Podocalyxin as a Prognostic Marker in Gastric Cancer

Laitinen Alli
Böckelman Camilla
Hagström Jaana
Kokkola Arto
Fermér Christian
Nilsson Olle
Haglund Caj

December 2015

Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...

Cox uni- and multivariate analysis of relative risk of death from pancreatic ductal adenocarcinoma by PODXL expression.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Abbrevations CI = Confidence interval, HR = Hazard ratio. Multivariate analysis included adjustme...

Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.

Heby, Margareta
Elebro, Jacob
Nodin, Björn
Jirström, Karin
Eberhard, Jakob

January 2015

Adenocarcinoma of the periampullary region is associated with poor prognosis and new prognostic and ...

A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers

Winter Jordan M.
Tang Laura H.
Klimstra David S.
Brennan Murray F.
Brody Jonathan R.
Rocha Flavio G.
Jia Xiaoyu
Qin Li-Xuan
D’Angelica Michael I.
DeMatteo Ronald P.
Fong Yuman
Jarnagin William R.
O’Reilly Eileen M.
Allen Peter J.

July 2012

One–fifth of patients with seemingly ‘curable’ pancreatic ductal adenocarcinoma (PDA) experience an ...

Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients.

Keisuke Taniuchi
Mutsuo Furihata
Seiji Naganuma
Masahiko Sakaguchi
Toshiji Saibara

January 2019

We previously reported that overexpression of PODXL, BCL7B, and ARHGEF4 in pancreatic cancer tissue ...

Biomarkers in pancreatic and other periampullary cancers - some familiar and one new

Heby, Margareta

January 2018

AbstractBackground: Adenocarcinomas arising in the area around the papilla of Vater are referred to ...

Clinical implications of biological markers in pancreatic ductal adenocarcinoma.

Giovinazzo F
Turri G
Zanini S
Butturini G
SCARPA, Aldo
BASSI, Claudio

January 2012

Pancreatic Ductal Adenocarcinoma (PDAC) is a malignant neoplasm and is the fourth leading cause of c...

Immunophenotypes of pancreatic ductal adenocarcinoma:Meta-analysis of transcriptional subtypes

de Santiago, Ines
Yau, Christopher
Heij, Lara
Middleton, Mark R.
Markowetz, Florian
Grabsch, Heike
Dustin, Michael L.
Sivakumar, Shivan

August 2019

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of...

Measurement of serum PODXL concentration for detection of pancreatic cancer

Taniuchi K
Tsuboi M
Sakaguchi M
Saibara T

March 2018

Keisuke Taniuchi,1,2 Makiko Tsuboi,2 Masahiko Sakaguchi,3,4 Toshiji Saibara1,2 1Department of Endos...

Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only

Ottenhof, Niki A.
Morsink, Folkert H. M.
ten Kate, Fiebo
van Noorden, Cornelis J. F.
Offerhaus, G. Johan A.

January 2012

Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rat...

Immunohistochemical staining pattern of PODXL by polyclonal antibody HPA 2110 in pancreatic ductal adenocarcinoma.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative...

Concomitant positivity by two PODXL antibodies.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Cancer-specific survival analysis according to the Kaplan-Meier method for combined expression of...

Immunohistochemical staining pattern of PODXL by monoclonal antibody HES9 in pancreatic ductal adenocarcinoma.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative...

RESEARCH ARTICLE Podocalyxin Is a Marker of Poor Prognosis in

Pancreatic Ductal Adenocarcinoma
Kapo Saukkonen
Jaana Hagström
Harri Mustonen
Anne Juuti
Stig Nordling
Christian Fermér
Olle Nilsson
Caj Haglund

August 2016

Aim of the Study Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates...

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma

Saukkonen Kapo
Hagström Jaana
Mustonen Harri
Juuti Anne
Nordling Stig
Fermér Christian
Nilsson Olle
Seppänen Hanna
Haglund Caj

June 2015

Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers ...

Podocalyxin as a Prognostic Marker in Gastric Cancer

Laitinen Alli
Böckelman Camilla
Hagström Jaana
Kokkola Arto
Fermér Christian
Nilsson Olle
Haglund Caj

December 2015

Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...

Cox uni- and multivariate analysis of relative risk of death from pancreatic ductal adenocarcinoma by PODXL expression.

Kapo Saukkonen (751176)
Jaana Hagström (476954)
Harri Mustonen (641410)
Anne Juuti (132978)
Stig Nordling (751177)
Christian Fermér (751178)
Olle Nilsson (232687)
Hanna Seppänen (751179)
Caj Haglund (476956)

June 2015

Abbrevations CI = Confidence interval, HR = Hazard ratio. Multivariate analysis included adjustme...

Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.

Heby, Margareta
Elebro, Jacob
Nodin, Björn
Jirström, Karin
Eberhard, Jakob

January 2015

Adenocarcinoma of the periampullary region is associated with poor prognosis and new prognostic and ...

A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers

Winter Jordan M.
Tang Laura H.
Klimstra David S.
Brennan Murray F.
Brody Jonathan R.
Rocha Flavio G.
Jia Xiaoyu
Qin Li-Xuan
D’Angelica Michael I.
DeMatteo Ronald P.
Fong Yuman
Jarnagin William R.
O’Reilly Eileen M.
Allen Peter J.

July 2012

One–fifth of patients with seemingly ‘curable’ pancreatic ductal adenocarcinoma (PDA) experience an ...

Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients.

Keisuke Taniuchi
Mutsuo Furihata
Seiji Naganuma
Masahiko Sakaguchi
Toshiji Saibara

January 2019

We previously reported that overexpression of PODXL, BCL7B, and ARHGEF4 in pancreatic cancer tissue ...

Biomarkers in pancreatic and other periampullary cancers - some familiar and one new

Heby, Margareta

January 2018

AbstractBackground: Adenocarcinomas arising in the area around the papilla of Vater are referred to ...

Clinical implications of biological markers in pancreatic ductal adenocarcinoma.

Giovinazzo F
Turri G
Zanini S
Butturini G
SCARPA, Aldo
BASSI, Claudio

January 2012

Pancreatic Ductal Adenocarcinoma (PDAC) is a malignant neoplasm and is the fourth leading cause of c...

Immunophenotypes of pancreatic ductal adenocarcinoma:Meta-analysis of transcriptional subtypes

de Santiago, Ines
Yau, Christopher
Heij, Lara
Middleton, Mark R.
Markowetz, Florian
Grabsch, Heike
Dustin, Michael L.
Sivakumar, Shivan

August 2019

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of...

Measurement of serum PODXL concentration for detection of pancreatic cancer

Taniuchi K
Tsuboi M
Sakaguchi M
Saibara T

March 2018

Keisuke Taniuchi,1,2 Makiko Tsuboi,2 Masahiko Sakaguchi,3,4 Toshiji Saibara1,2 1Department of Endos...

Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only

Ottenhof, Niki A.
Morsink, Folkert H. M.
ten Kate, Fiebo
van Noorden, Cornelis J. F.
Offerhaus, G. Johan A.

January 2012

Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rat...

Membranous PODXL expression by polyclonal antibody HPA 2110 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.

Abstract

Extracted data

Membranous PODXL expression by polyclonal antibody HPA 2110 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.

Abstract

Extracted data

Related items

Related items